Stay updated on Lenvatinib and Pembrolizumab in HCC Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib and Pembrolizumab in HCC Clinical Trial page.

Latest updates to the Lenvatinib and Pembrolizumab in HCC Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant changes, including the removal of detailed study information regarding the safety and efficacy of lenvatinib in combination with pembrolizumab for treating advanced hepatocellular carcinoma, and the addition of new identifiers and collaborators.SummaryDifference15%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.6%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.6%
Stay in the know with updates to Lenvatinib and Pembrolizumab in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib and Pembrolizumab in HCC Clinical Trial page.